Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IOP Lowering Medications · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| IOP Lowering Medications | DRUG | - |
Adults of Japanese Ethnicity
Top 3 of 5 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular, high elution |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Bimatoprost ophthalmic solution |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | bimatoprost |
IOP Lowering Medications is an investigational small molecule being developed for the treatment of open-angle glaucoma. It is designed to lower intraocular pressure in patients with this condition. The drug is currently in Phase 3 clinical development and has not yet been approved by regulatory authorities.
IOP Lowering Medications is being developed by Alcon Inc., a company traded on the New York Stock Exchange under the ticker symbol ALC. Alcon is conducting clinical trials to evaluate the safety and efficacy of this investigational therapy for open-angle glaucoma.
IOP Lowering Medications is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. The Phase 3 trial has been completed, and the drug remains under evaluation for the treatment of open-angle glaucoma.
IOP Lowering Medications has one completed Phase 3 clinical trial registered under NCT00047593. The study, titled 'Phase 3 Study Comparing IOP Lowering in OAG or OH in Japanese Subjects C-01-98,' was a randomized, double-blind trial conducted in the United States for patients with open-angle glaucoma or ocular hypertension.
IOP Lowering Medications is not FDA approved. It is an investigational drug currently in Phase 3 clinical development. The completed Phase 3 trial (NCT00047593) evaluated its use in open-angle glaucoma and ocular hypertension, but regulatory approval has not been granted.